We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-7.44%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$699M
AUM Growth
-$155M
Cap. Flow
-$60.3M
Cap. Flow %
-8.64%
Top 10 Hldgs %
51.76%
Holding
52
New
12
Increased
5
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$27.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$20.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$17.2M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.6M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$14.4M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$31.7M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$20.7M
3
BCYC
Bicycle Therapeutics
BCYC
+$17.2M
4
VTYX
Ventyx Biosciences
VTYX
+$15M
5
FULC icon
Fulcrum Therapeutics
FULC
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-180,000
Closed -$6.84M
RXDX
52
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-50,000
Closed -$5.5M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2023 Portfolio in Review

As of Q1 2023, Logos Global Management held 52 positions worth $699M, down 18% from $854M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management withdrew a net $60.3M in Q1 2023, closing 9 positions and reducing 17 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $20.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Biogen worth $27.8M.

  • Logos Global Management's largest Q1 2023 buy was Biogen: 100,000 shares worth $27.8M.
  • Logos Global Management added most to Rocket Pharmaceuticals in Q1 2023, an estimated $2.94M increase.
  • Logos Global Management's biggest Q1 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $31.7M.
  • Logos Global Management fully exited Arcutis Biotherapeutics in Q1 2023, selling an estimated $20.7M.
  • Logos Global Management's ten largest holdings make up 52% of its $699M portfolio in Q1 2023.
  • Logos Global Management opened 12 new positions and closed 9 in Q1 2023.
  • Logos Global Management's portfolio value fell 18% quarter-over-quarter to $699M.

Based on Logos Global Management's 13F filing for Q1 2023, filed 15 May 2023.